Now, just two months after the blockbuster offering, Wall Street has become more bearish on the company's stock.
As of this week, seven equity research analysts who cover Twitter are rating the shares a "sell," according to FactSet research.
That's the same number who rate them a buy, according to FactSet.
By contrast, the 1,800 technology companies in the S&P 500 Index have an average buy-to-sell ratio of 10-to-1, according to John Butters, senior earnings analyst at FactSet.
Another 12 analysts who publish research on Twitter are on the fence about the stock's prospects, rating them a "hold" or "equal-weight."
Top Building Product Companies To Watch In Right Now: Guggenheim CurrencyShares Euro Trust (FXE)
Guggenheim CurrencyShares Euro Trust, formerly CurrencyShares Euro Trust, is a grantor trust. The Trust issues shares (the Shares) in blocks of 50,000 (a Basket) in exchange for deposits of euro and distributes euro in connection with the redemption of Baskets. The investment objective of the Trust is for the Shares to reflect the price of euro plus accrued interest. The Shares are intended to offer investors an opportunity to participate in the market for the euro through an investment in securities. The Shares are bought and sold on NYSE Arca. The Shares are backed by the assets of the Trust, which does not hold or use derivative products. The Trust holds euro and, from time to time, issues Baskets in exchange for deposits of euro and distributes euro in connection with redemptions of Baskets.
The Sponsor is Rydex Specialized Products LLC. The Bank of New York Mellon serves as the Trustee. JPMorgan Chase Bank, N.A., London Branch is the Depository. The Depository maintains two deposit accounts for the Trust, a primary deposit account which may earn interest and a secondary deposit account which does not earn interest (Deposit Accounts). The secondary deposit account is used to account for interest received and paid out on creations and redemptions of Baskets. The secondary account is also used to account for interest, if any, earned on the primary deposit account, pay Trust expenses and distribute any excess interest to Shareholders on a monthly basis.
Advisors' Opinion:- [By Ben Levisohn]
The euro has dropped about 0.8% against the dollar, while the CurrencyShares Euro Trust ETF (FXE) has dropped 0.7% to $136.71 and the Currency Shares Japanese Yen Trust ETF (FXY) has fallen 1%. The ProShares UltrasShort Euro ETF (EUO) has gained 1.3% to $16.77, while the ProShares UltraShort Yen (YCS) has gained 1.9% to $66.58.
Top Forestry Stocks To Buy For 2014: Addus HomeCare Corporation(ADUS)
Addus HomeCare Corporation provides a range of social and medical services to individuals in the home. The company serves individuals with special needs who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill, and disabled. It offers various health services that include personal care and assistance with activities of daily living, skilled nursing and rehabilitative therapies, and adult day care. The company?s Home and Community Services division offers assistance with bathing, grooming, dressing, personal hygiene and medication reminders, and other activities of daily living on a long-term, continuous basis, with an average duration of 20 months per consumer. Its Home Health Services division comprises physical, occupational, and speech therapy, as well as skilled nursing services, which are offered on a short-term, intermittent, or episodic basis to individuals recovering from an acute medical condition, with an average length of care of 80 days. The company?s payor clients include federal, state, and local government programs, such as Medicaid funded programs and Medicaid waiver programs; other state agencies and Medicare; and the Veterans Health Administration, commercial insurers, and private duty consumers. The company was formerly known as Addus Holding Corporation and changed its name to Addus HomeCare Corporation in September, 2006. Addus HomeCare Corporation was incorporated in 2006 and is headquartered in Palatine, Illinois.
Advisors' Opinion:- [By Monica Gerson]
Addus HomeCare (NASDAQ: ADUS) is projected to post its Q4 earnings at $0.25 per share on revenue of $68.07 million.
magicJack VocalTec (NASDAQ: CALL) is expected to post its Q4 earnings at $0.41 per share on revenue of $35.93 million.
Top Forestry Stocks To Buy For 2014: Capital Bank Financial Corp (CBF)
Capital Bank Financial Corp, formerly North American Financial Holdings, Inc., incorporated in 2009, is a bank holding Company. The Company focuses on creating a regional banking franchise in the southeastern region of the United States through organic growth and acquisitions of other banks. As of March 31, 2011, the Bank operated 82 branches in Florida, North Carolina and South Carolina. On July 16, 2010, the Bank acquired approximately $1.2 billion of assets and assumed approximately $960.1 million of deposits of three banks from the federal deposit insurance corporation (FDIC): First National Bank of the South in Spartanburg, South Carolina, Metro Bank of Dade County in Miami, Florida and Turnberry Bank in Aventura, Florida. On September 30, 2010 and January 28, 2011, the Bank consummated controlling investments in TIB Financial and Capital Bank Corp., respectively. The Bank�� products and services included commercial bank business, consumer bank business, Mortgage Banking, and Private Banking, Trust and Investment Management. In October 2012, it acquired Southern Community Financial Corp.
Lending activities
As of March 31, 2011, the Bank�� loans included: Real estate mortgage loans, Commercial and agricultural loans and Home equity loans. Real estate mortgage loans include: Commercial, Residential, and Construction and vacant land. As of March 31, 2011, covered loans were $656.6 million, representing 22.3% of its loan portfolio. As of March 31, 2011, non-covered loans were $2.3 billion, representing 77.6% of its loan portfolio. As of March 31, 2011, loans related to real estate totaled $2.6 billion (or 87% of the Bank�� total loan portfolio). At March 31, 2011, commercial real estate loans in all regions totaled $1.8 billion.
Investment activities
Investment securities represent a major portion of the Bank�� assets. As of March 31, 2011, the Bank�� investment securities included mortgage backed securities, United States government agen! cies, states and political subdivisions, corporate bonds, equity, collateralized debt obligations and foreign government. Of the securities in the portfolio, 94% were rated AAA, and 97% were rated A or higher.
Sources of Funds
As of March 31, 2011, the Bank�� deposits included Non-interest demand deposit accounts, Interest Bearing demand deposit accounts, Savings and Money Market. It also included Customer Time Deposits and Wholesale Time Deposits. At March 31, 2011, total deposits were $3.5 billion of which $3.4 billion (or 97%) were non-brokered deposits and $94.4 million (or 3%) were brokered deposits. At March 31, 2011, the Bank�� core deposits (which are all deposits other than time deposits) consisted of $463.2 million of non-interest checking, $430.7 million of negotiable order of withdrawal accounts, $157.5 million of savings accounts and $456.2 million of money market deposits.
The Bank competes with Bank of America, Wells Fargo, BB&T, First Citizens, Royal Bank of Canada, SunTrust, Regions, FNB United Corp., Toronto-Dominion, Synovus, First Financial, SCBT, JPMorgan Chase, Citigroup, EverBank, Fifth Third Bancorp, First Horizon, Pinnacle Financial, First South and U.S. Bancorp.
Advisors' Opinion:- [By Tim Melvin]
The year ahead should be a great one for the smaller bank stocks. Larger regionals like Huntington Bancorp (HBAN) and Capital Ban Financial (CBF) have made it clear they intend to grow by acquisition in the years ahead. Banks like First Merit (FMER) and First Merchants (FRME) have done deals in the past year and are open to doing more to increase their market share and footprints. This should be the year the floodgates open and we see the first wave of merger activity in small banks.
Top Forestry Stocks To Buy For 2014: United Therapeutics Corporation(UTHR)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases in the United States and internationally. It offers Remodulin, Tyvaso, and Adcirca for the treatment of pulmonary arterial hypertension (PAH). The company also develops Oral Treprostinil (UT-15C), a new drug application filed with the United States Food and Drug Administration for the treatment of PAH. Its development products under Phase III clinical trials include Oral Treprostinil (UT-15C) Combination Therapy for PAH; Ch14.18 monoclonal antibody (MAb) targeting Neuroblastoma; and Remodulin for the treatment of PAH in the United States, the United Kingdom, France, Germany, Italy, and Japan. The company?s development products under Phase I clinical trials comprise Beraprost-MR for PAH in North America, Europe, Mexico, South America, Egypt, India, South Africa, and Australia; 8H9 MAb targ eting Metastatic brain cancer; and IW001 for the treatment of Idiopathic pulmonary fibrosis and primary graft dysfunction. Its pre-clinical stage products consist of Glycobiology Antiviral Agents for viral infectious diseases; PLacental eXpanded cells targeting PAH; and pulmonary tissue replacement and remodeling products for the treatment of end-stage lung disease. The company serves pharmaceutical wholesalers through specialty pharmaceutical distributors and other distributors. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Advisors' Opinion:- [By Ben Levisohn]
United Therapeutics (UTHR) has zoomed to a 52-week high after a patent court gave it a partial victory in a lawsuit involving one of its drugs. ISI Group’s Mark Schoenebaum explains:
Agence France-Presse/Getty ImagesThe court ruling for the�United Therapeutics / Sandoz case was just posted. The judge ruled in favor of�United Therapeutics on the 2017 patent and in favor of Sandoz on the 2029 patent (United Therapeutics patent valid but Sandoz does not infringe) giving�United Therapeutics likely an additional 3 years protection on Remodulin.
Investors were skeptical of a win on the 2017 patent (and gave very little credit to the 2029 patent given it was only on the diluent and Sandoz could have possibly just gotten a carve-out on the label). So this is close to a best case scenario in our view as the big overhang on�United Therapeutics appears to now be behind them and investors can consider owning�United Therapeutics for the potential for better than expected oral Orenitram sales.
An additional 3 years of Remodulin protection adds ~$10 to our DCF.
Leerink’s Joseph Schwartz and Paul Matteis doesn’t think the news is as good as the market thinks it is:
While the order is likely to lead to a modest raise of near term consensus estimates, we believe that the decision re-affirms our long-term cautious view on�United Therapeutics shares given the 1) near certainty now that Remodulin will go generic in 2H17 and 2) greater need for�United Therapeutics to create value through creatively deploying its free cash flow, which in recent history has mostly been used to fund operations and buy back stock. Thus, while the ruling today likely solifidies United Therapeutics’ 2015-2016 earnings potential, based on our sensitivity analysis we believe that the near certain presence of a generic in 2017 implies significant downside to the NPV of the remodulin franchise, contrary to the positive stock reaction to the
- [By John Udovich]
The biotech sector may have lost some favor on Wall Street, but there is still plenty of interesting or overlooked news about the sector and/or biotech stocks like InterMune Inc (NASDAQ: ITMN), Biogen Idec Inc (NASDAQ: BIIB), Alexion Pharmaceuticals, Inc (NASDAQ: ALXN), United Therapeutics Corporation (NASDAQ: UTHR) and TNI BioTech, Inc (OTCMKTS: TNIB):
- [By Ben Levisohn]
Look up in the sky! It’s a bird! It’s a plane! It’s Santa Claus! No. It’s United Therapeutics (UTHR).
ReutersShares of the United Therapeutics have surged 23% to $107.65, on what’s looking to be a pretty decent day for biotech stocks. The iShares Nasdaq Biotechnology Index ETF (IBB) has gained 0.9% to $225.75, as Gilead Sciences (GILD) has risen 0.7% to $75.16 and Celgene (CELG) has ticked up 0.4% to $168.09.
Top Forestry Stocks To Buy For 2014: Wajax Corp (WJX)
Wajax Corporation (Wajax), is engaged in the sale and after-sales parts and service support of equipment, power systems and industrial components. Wajax�� three business divisions include equipment,power systems and industrial components. Its equipment division is engaged in the distribution, rental, modification and servicing of mobile equipment from manufacturers. It Power Systems is engaged in the distribution, rental and servicing of engines, transmissions and generators for on-highway, off-highway and electric power generation applications. Industrial components is engaged in the distribution, servicing, custom design and assembly of industrial components for in-plant customers and original equipment manufacturers. The Company�� products include excavators, lift trucks, mining trucks and shovels, forest harvesting equipment, utility equipment, loader backhoes, container handlers, cranes, diesel and natural gas engines, transmissions and power generators and bearings. Advisors' Opinion:- [By John Heinzl]
For example, BMO Nesbitt Burns analyst Bert Powell recently raised his price target on Wajax (WJX) to $41.50 from $35.50 because, as he explained in a note, he believes the company is poised for a recovery. The new target reflects his expectation that the stock will trade at 11 times his 2015 earnings per share estimate of $3.77��ts average P/E multiple historically.
No comments:
Post a Comment